Differences Amid Bone Marrow and Cord Blood Hematopoietic Stem/Progenitor Cell Division Kinetics

被引:34
作者
Da Silva, Claudia Lobato [1 ]
Goncalves, Raquel [1 ]
Porada, Christopher D. [1 ]
Ascensao, Joao L. [2 ,3 ]
Zanjani, Esmail D. [1 ]
Cabral, Joaquim M. S.
Almeida-Porada, Graca [1 ]
机构
[1] Univ Nevada, Dept Anim Biotechnol, Reno, NV 89557 USA
[2] George Washington Univ, Sch Med, Washington, DC USA
[3] George Washington Univ, Dept Med, VA Med Ctr, Washington, DC USA
关键词
EX-VIVO EXPANSION; HIGH-DOSE CHEMOTHERAPY; STEM-CELLS; CD34; ANTIGEN; REVERSIBLE EXPRESSION; BREAST-CANCER; PROGENITORS; ENGRAFTMENT; SUPPORTS; LIGAND;
D O I
10.1002/jcp.21736
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Human hematopoietic stem/progenitor cells (HSC) isolated based upon specific patterns of CD34 and CD38 expression, despite phenotypically identical, were found to be functionally heterogeneous, raising the possibility that reversible expression of these antigens may occur during cellular activation and/or proliferation. In these studies, we combined PKH67 tracking with CD34/CD38 immunostaining to compare cell division kinetics between human bone marrow (BM) and cord blood (CB)-derived HSC expanded in a serum-free/stromal-based system for 14 days (d), and correlated CD34 and CD38 expression with the cell divisional history. CB cells began dividing 24 h earlier than BM cells, and significantly higher numbers underwent mitosis during the time in culture. By d10, over 55% of the CB-cells reached the ninth generation, whereas BM-cells were mostly distributed between the fifth and seventh generation. By d14, all CB cells had undergone multiple cell divisions, while 0.7-3.8% of BM CD34(+) cells remained quiescent. Furthermore, the percentage of BM cells expressing CD34 decreased from 60.8 +/- 6.3% to 30.6 +/- 6.7% prior to initiating division, suggesting that downmodulation of this antigen occurred before commencement of proliferation. Moreover, with BM, all primitive CD34(+) CD38(-) cells present at the end of culture arose from proliferating CD34(+) CD38(+); cells that downregulated CD38 expression, while in CB, a CD34(+) CD38(-) population was maintained throughout culture. These studies show that BM and CB cells differ significantly in cell division kinetics and expression of CD34 and CD38, and that the inherent modulation of these antigens during ex vivo expansion may lead to erroneous quantification of the stem cell content of the expanded graft. J. Cell. Physiol. 220: 102-111, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:102 / 111
页数:10
相关论文
共 46 条
[1]   Evaluation of serum-free culture conditions able to support the ex vivo expansion and engraftment of human hematopoietic stem cells in the human-to-sheep xenograft model [J].
Almeida-Porada, G ;
Brown, RL ;
MacKintosh, FR ;
Zanjani, ED .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (05) :683-693
[2]  
BAUMHUETER S, 1994, BLOOD, V84, P2554
[3]   ANTIGEN CD34+ MARROW-CELLS ENGRAFT LETHALLY IRRADIATED BABOONS [J].
BERENSON, RJ ;
ANDREWS, RG ;
BENSINGER, WI ;
KALAMASZ, D ;
KNITTER, G ;
BUCKNER, CD ;
BERNSTEIN, ID .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (03) :951-955
[4]  
BERENSON RJ, 1991, BLOOD, V77, P1717
[5]   A newly discovered class of human hematopoietic cells with SCID-repopulating activity [J].
Bhatia, M ;
Bonnet, D ;
Murdoch, B ;
Gan, OI ;
Dick, JE .
NATURE MEDICINE, 1998, 4 (09) :1038-1045
[6]   Ex vivo expansion of autologous bone marrow CD34+ cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons [J].
Brandt, JE ;
Bartholomew, AM ;
Fortman, JD ;
Nelson, MC ;
Bruno, E ;
Chen, LM ;
Turian, JV ;
Davis, TA ;
Chute, JP ;
Hoffman, R .
BLOOD, 1999, 94 (01) :106-113
[7]  
BREARD J, 1980, J IMMUNOL, V124, P1943
[8]   Potential of CD34 in the regulation of symmetrical and asymmetrical divisions by hematopoietic progenitor cells [J].
Bullock, Tabitha E. ;
Wen, Baiping ;
Marley, Stephen B. ;
Gordon, Myrtle Y. .
STEM CELLS, 2007, 25 (04) :844-851
[9]  
CHRYSLER GR, 2004, CORD BLOOD BIOL IMMU
[10]  
CIVIN CI, 1984, J IMMUNOL, V133, P157